Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for naloxone hydrochloride injections approved and issued by the State Drug Administration. Indications for the drug include antagonistic respiratory depression after opioid complex anesthesia, reversal of respiratory depression in opioid overdose, relief from acute alcohol poisoning, and diagnosis of acute opioid overdose. Huahai Pharmaceutical said that the approval of this product further enriches the company's product line and helps enhance market competitiveness. However, at the same time, it is reminded that pharmaceutical production and sales are affected by policies and market environments, and investors need to make careful decisions.

Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for naloxone hydrochloride injections approved and issued by the State Drug Administration. Indications for the drug include antagonistic respiratory depression after opioid complex anesthesia, reversal of respiratory depression in opioid overdose, relief from acute alcohol poisoning, and diagnosis of acute opioid overdose. Huahai Pharmaceutical said that the approval of this product further enriches the company's product line and helps enhance market competitiveness. However, at the same time, it is reminded that pharmaceutical production and sales are affected by policies and market environments, and investors need to make careful decisions.